GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Shares Outstanding (EOP)

Kintor Pharmaceutical (HKSE:09939) Shares Outstanding (EOP) : 447.50 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Kintor Pharmaceutical's shares outstanding for the quarter that ended in Dec. 2023 was 447.50 Mil.

Kintor Pharmaceutical's quarterly shares outstanding stayed the same from Jun. 2023 (447.50 Mil) to Dec. 2023 (447.50 Mil).

Kintor Pharmaceutical's annual shares outstanding stayed the same from Dec. 2022 (447.50 Mil) to Dec. 2023 (447.50 Mil).


Kintor Pharmaceutical Shares Outstanding (EOP) Historical Data

The historical data trend for Kintor Pharmaceutical's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Shares Outstanding (EOP) Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 369.39 369.39 387.59 447.50 447.50

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 387.59 387.59 447.50 447.50 447.50

Competitive Comparison of Kintor Pharmaceutical's Shares Outstanding (EOP)

For the Biotechnology subindustry, Kintor Pharmaceutical's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintor Pharmaceutical's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's Shares Outstanding (EOP) falls into.



Kintor Pharmaceutical Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Kintor Pharmaceutical  (HKSE:09939) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Kintor Pharmaceutical Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical (HKSE:09939) Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines